Merck & Co., Inc. (MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.1
We believe there is potential upside for MRK over the next few quarters, driven by robust growth in its core product: (i) Keytruda – treatment of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC; (ii) Gardasil –vaccine for Human Papillomavirus (HPV)
Ramp-up of Keytruda and strong Gardasil sales. MRK reported Keytruda sales of US$2.63bn (+30% YoY) for the 2Q19 results due to strong uptake in the NSCLC space. We expect Keytruda to be one of the key drugs in the treatment of NSCLC following approvals from various countries such as the US, EU and China. We believe the Keytruda-chemo combo approved in EU will provide significant upside for EU revenue growth. The drug also sees opportunity in the RCC market as the Keytruda-Inlyta combo was launched in the US this year and awaiting ex-US launch. We see an acceleration of Gardasil growth due to high demand for the HPV vaccine in both US and ex-US. Gardasil revenue grew 50% constant currency (CC) YoY in 2Q19, as compared to 31% YoY in 1Q19.
Higher growth in the China market. MRK announced robust results in China with sales in 2Q19 rising 51% YoY, due to new launches (Keytruda, Lynparza, Lenvima, Gardasil) and the drug Januvia making it on the national reimbursement drug list (NRDL) listing. The pharmaceutical giant is also benefiting from the metastatic melanoma launch this year and the approval for Keytruda’s First Anti-PD-1 Therapy for lung cancer, which is likely to make the NRDL listing.
Bolt-on acquisitions to enhance organic growth. MRK maintains that it is focused on making “non-disruptive” bolt-on acquisitions. MRK commented that it is focused on targets to boost a wide spectrum of therapeutic areas. We believe the acquisitions will speed up the R&D programs (taking an average of 6-7 years) and provide additional synergies such as combination therapies.
We have a TECHNICAL BUY rating for MRK. MRK is currently trading at a P/E ratio of 17.9, which is below its historical average. We believe the stock price of MRK is attractive given its potential upside from the strong organic growth led by Keytruda.
 Source: Bloomberg
Support 1: 131.37 Resistance 1:141.68
The stock price of MRK exhibits strong bullish momentum since the start of 1Q19. Based on the weekly technical chart, we believe the rally will continue:
———- 200 periods MA
———- 50 periods MA
———- 22 periods MA